



The European Agency for the Evaluation of Medicinal Products

London, 4 September 2003
Doc. Ref: EMEA/23230/03/Final

PRESS RELEASE
European Agency for the Evaluation of Medicinal Products:
Committee for Proprietary Medicinal Products
Extraordinary meeting, 3 September 2003

The Committee confirmed its negative opinion for **Serostim** (somatropin), from Ares Serono, intended for the treatment of AIDS-related wasting syndrome. This final opinion is adopted following an appeal by the applicant of the initial CPMP opinion in April 2003. The opinion was adopted after hearing an oral explanation from the applicant and having considered the grounds for appeal.

An updated summary of the opinion is available on the EMEA web site: <http://www.emea.eu.int>

Other items discussed will be published together with the September CPMP meeting report.

--ENDS--

Media enquiries only please contact Martin Harvey Allchurch
EMEA press officer, Tel. (44-20) 74 18 84 27, E-mail: martin.harvey-allchurch@emea.eu.int